Nucleic acid therapeutics: Past, present, and future
Nucleic acid therapeutics have become increasingly recognized in recent years for their capability to target both coding and non-coding sequences. Several types of nucleic acid modalities, including siRNA, mRNA, aptamer, along with antisense oligo, have been approved by regulatory bodies for therape...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Molecular Therapy: Nucleic Acids |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253124003275 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841526271522111488 |
|---|---|
| author | Sajid Naeem Ju Zhang Yang Zhang Yu Wang |
| author_facet | Sajid Naeem Ju Zhang Yang Zhang Yu Wang |
| author_sort | Sajid Naeem |
| collection | DOAJ |
| description | Nucleic acid therapeutics have become increasingly recognized in recent years for their capability to target both coding and non-coding sequences. Several types of nucleic acid modalities, including siRNA, mRNA, aptamer, along with antisense oligo, have been approved by regulatory bodies for therapeutic use. The field of nucleic acid therapeutics has been brought to the forefront by the rapid development of vaccines against COVID-19, followed by a number of approvals for clinical use including much anticipated CRISPR-Cas9. However, obstacles such as the difficulty of achieving efficient and targeted delivery to diseased sites remain. This review provides an overview of nucleic acid therapeutics and highlights substantial advancements, including critical engineering, conjugation, and delivery strategies, that are paving the way for their growing role in modern medicine. |
| format | Article |
| id | doaj-art-56f7d10d037c4b2aa6e92962b44bb246 |
| institution | Kabale University |
| issn | 2162-2531 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Nucleic Acids |
| spelling | doaj-art-56f7d10d037c4b2aa6e92962b44bb2462025-01-17T04:49:28ZengElsevierMolecular Therapy: Nucleic Acids2162-25312025-03-01361102440Nucleic acid therapeutics: Past, present, and futureSajid Naeem0Ju Zhang1Yang Zhang2Yu Wang3College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China; College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, ChinaCollege of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China; College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, ChinaSchool of Biomedical Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, Guangdong, China; Corresponding author: Yang Zhang, School of Biomedical Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, Guangdong, China.College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China; Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China; Corresponding author: Yu Wang, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China.Nucleic acid therapeutics have become increasingly recognized in recent years for their capability to target both coding and non-coding sequences. Several types of nucleic acid modalities, including siRNA, mRNA, aptamer, along with antisense oligo, have been approved by regulatory bodies for therapeutic use. The field of nucleic acid therapeutics has been brought to the forefront by the rapid development of vaccines against COVID-19, followed by a number of approvals for clinical use including much anticipated CRISPR-Cas9. However, obstacles such as the difficulty of achieving efficient and targeted delivery to diseased sites remain. This review provides an overview of nucleic acid therapeutics and highlights substantial advancements, including critical engineering, conjugation, and delivery strategies, that are paving the way for their growing role in modern medicine.http://www.sciencedirect.com/science/article/pii/S2162253124003275MT: Oligonucleotides: Therapies and Applicationsnucleic acid therapeuticsantisense oligonucleotidessmall interfering RNAaptamermessenger RNA |
| spellingShingle | Sajid Naeem Ju Zhang Yang Zhang Yu Wang Nucleic acid therapeutics: Past, present, and future Molecular Therapy: Nucleic Acids MT: Oligonucleotides: Therapies and Applications nucleic acid therapeutics antisense oligonucleotides small interfering RNA aptamer messenger RNA |
| title | Nucleic acid therapeutics: Past, present, and future |
| title_full | Nucleic acid therapeutics: Past, present, and future |
| title_fullStr | Nucleic acid therapeutics: Past, present, and future |
| title_full_unstemmed | Nucleic acid therapeutics: Past, present, and future |
| title_short | Nucleic acid therapeutics: Past, present, and future |
| title_sort | nucleic acid therapeutics past present and future |
| topic | MT: Oligonucleotides: Therapies and Applications nucleic acid therapeutics antisense oligonucleotides small interfering RNA aptamer messenger RNA |
| url | http://www.sciencedirect.com/science/article/pii/S2162253124003275 |
| work_keys_str_mv | AT sajidnaeem nucleicacidtherapeuticspastpresentandfuture AT juzhang nucleicacidtherapeuticspastpresentandfuture AT yangzhang nucleicacidtherapeuticspastpresentandfuture AT yuwang nucleicacidtherapeuticspastpresentandfuture |